European Union
ENHERTU Receives EU Approval for HER2 Positive Metastatic Breast Cancer
The European Commission (EC) has approved Daiichi Sankyo and AstraZeneca's ENHERTU (trastuzumab deruxtecan) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti-HER2-based regimens. This approval follows the positive opinion of the Committee